Work

Supplementary Data from A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma

Year: 2023

Type: supplementary-materials

Abstract: SF1: NRAS mutant melanoma sensitivity to trametinib and palbociclib treatment; SF2: MELJUSO ORF Screen Optimization and Validation; SF3: MELJUSO CRISPR Screen Optimization and Validation; SF4: EGFR-PI3K-AKT signaling modulates resistance to trametinib/palbociclib treatment in NRAS mutant melanoma cell lines; SF5: RAS signaling modulates resistance to trametinib/palbociclib treatment in NRAS mutant melanoma cell lines; SF6: EGFR-PI3K-AKT signaling cascade differentially replaces loss of genetic NRAS in NRAS mutant melanoma cell lines; SF7: Active KRAS can replace loss of genetic NRAS

DOI: 10.1158/0008-5472.22423682.v1

Authors: Tikvah K. Hayes, Flora Luo, Ofir Cohen, Amy B. Goodale, Yenarae Lee, Sasha Pantel, Mukta Bagul, Federica Piccioni, David E. Root, Levi A. Garraway, Matthew Meyerson, Cory M. Johannessen

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361843067

Cites:

Cited by:

Related to: 10